

Patient Name: 양유석
Gender: M
Sample ID: N25-71

Primary Tumor Site: Bronchus
Collection Date: 2025.06.13

Sample Cancer Type: Non-Small Cell Lung Cancer

Table of Contents	Page	Report Highlights
Variant Details	2	2 Relevant Biomarkers
Biomarker Descriptions	3	52 Therapies Available
Alert Details	7	77 Clinical Trials
Relevant Therapy Summary	11	

Relevant Non-Small Cell Lung Cancer Findings

Gene	Finding	Gene	Finding
ALK	None detected	MET	None detected
BRAF	None detected	NRG1	None detected
EGFR	None detected	NTRK1	None detected
ERBB2	ERBB2 amplification	NTRK2	None detected
FGFR1	None detected	NTRK3	None detected
FGFR2	None detected	RET	None detected
FGFR3	None detected	ROS1	None detected
KRAS	None detected		

Genomic Alteration	Finding
Tumor Mutational Burden	0.94 Mut/Mb measured

Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IA	ERBB2 amplification erb-b2 receptor tyrosine kinase 2 Locus: chr17:37863255	trastuzumab deruxtecan ^{1 / II+}	lapatinib + hormone therapy ^{1, 2 / I, II+} lapatinib + trastuzumab ^{2 / I, II+} pertuzumab + trastuzumab + chemotherapy ^{1, 2 / I, II+} trastuzumab + tucatinib ^{1 / I, II+} trastuzumab deruxtecan ^{1, 2 / I, II+} trastuzumab[†] + chemotherapy ^{1, 2 / I, II+} trastuzumab[†] + hormone therapy ^{2 / I, II+} pembrolizumab + trastuzumab + chemotherapy ^{1, 2 / I} ado-trastuzumab emtansine ^{1, 2 / II+} lapatinib + chemotherapy ^{1, 2 / II+}	74

* Public data sources included in relevant therapies: FDA¹, NCCN, EMA², ESMO
* Public data sources included in prognostic and diagnostic significance: NCCN, ESMO
† Includes biosimilars/generics
Line of therapy: I: First-line therapy, II+: Other line of therapy
Tier Reference: Li et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017 Jan;19(1):4-23.

Relevant Biomarkers (continued)

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
			margetuximab + chemotherapy ^{1 / II+} neratinib ^{1, 2 / II+} neratinib + chemotherapy ^{1 / II+} trastuzumab + tucatinib + chemotherapy ^{1, 2 / II+} trastuzumab ^{† 1, 2 / II+} zanidatamab ^{1 / II+} pertuzumab/trastuzumab/hyaluronidase-zzxf + chemotherapy ^{1, 2} trastuzumab and hyaluronidase-oysk ¹ trastuzumab and hyaluronidase-oysk + chemotherapy ¹ pertuzumab + trastuzumab ^{I, II+} pertuzumab + trastuzumab + hormone therapy ^{I, II+} lapatinib + trastuzumab + hormone therapy ^I abemaciclib + trastuzumab + hormone therapy ^{II+} ado-trastuzumab emtansine + hormone therapy ^{II+} hormone therapy ^{II+} margetuximab ^{II+} pertuzumab + trastuzumab + hormone therapy + chemotherapy ^{II+} trastuzumab + hormone therapy + chemotherapy ^{II+}	
IIC	TP53 p.(R175H) c.524G>A tumor protein p53 Allele Frequency: 9.10% Locus: chr17:7578406 Transcript: NM_000546.6	None*	None*	3

* Public data sources included in relevant therapies: FDA¹, NCCN, EMA², ESMO
* Public data sources included in prognostic and diagnostic significance: NCCN, ESMO
† Includes biosimilars/generics
Line of therapy: I: First-line therapy, II+: Other line of therapy
Tier Reference: Li et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017 Jan;19(1):4-23.

 Alerts informed by public data sources:  Contraindicated,  Resistance,  Breakthrough,  Fast Track

ERBB2 amplification  CT-0508¹, CT-0525¹

Public data sources included in alerts: FDA¹, NCCN, EMA², ESMO

Prevalent cancer biomarkers without relevant evidence based on included data sources
ESR1 p.(R555H) c.1664G>A, Microsatellite stable, ZFHX3 p.(S1644*) c.4929_4929delCinsTT, Tumor Mutational Burden

Variant Details

DNA Sequence Variants							
Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect
TP53	p.(R175H)	c.524G>A	COSM10648	chr17:7578406	9.10%	NM_000546.6	missense

Variant Details (continued)

DNA Sequence Variants (continued)

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect
ESR1	p.(R555H)	c.1664G>A	.	chr6:152419977	40.64%	NM_001122740.2	missense
ZFXH3	p.(S1644*)	c.4929_4929delCinsTT	.	chr16:72831652	5.50%	NM_006885.4	nonsense
MAP3K1	p.([A117=;S118C])	c.351_352delGAinsCT	.	chr5:56111751	45.80%	NM_005921.2	synonymous, missense
LAMA2	p.(L2595V)	c.7783C>G	.	chr6:129807652	7.76%	NM_000426.4	missense
BRIP1	p.([E879=;S880P])	c.2637_2638delATinsG C	.	chr17:59763464	5.56%	NM_032043.3	synonymous, missense

Copy Number Variations

Gene	Locus	Copy Number	CNV Ratio
ERBB2	chr17:37863255	65.6	13.72

Biomarker Descriptions

ERBB2 amplification

erb-b2 receptor tyrosine kinase 2

Background: The ERBB2 gene encodes the erb-b2 receptor tyrosine kinase 2, a member of the human epidermal growth factor receptor (HER) family. Along with ERBB2/HER2, EGFR/ERBB1/HER1, ERBB3/HER3, and ERBB4/HER4 make up the HER protein family⁸⁹. All ERBB/HER proteins encode transmembrane receptor tyrosine kinases. However, ERBB2/HER2 is an orphan receptor with no known ligand. ERBB2 preferentially binds other ligand bound ERBB/HER family members to form hetero-dimers resulting in the activation of ERBB2 tyrosine kinase activity and subsequent activation of the PI3K/AKT/MTOR and RAS/RAF/MAPK/ERK signaling pathways which promote cell proliferation, differentiation, and survival⁹⁰. Recurrent focal amplification of the ERBB2 gene leads to increased expression in several cancer types. ERBB2 overexpression in immortalized cell lines is oncogenic and leads to ERBB2 homo-dimerization and activation without ligand binding^{91,92,93}.

Alterations and prevalence: ERBB2 gene amplification occurs in 10-20% of breast, esophageal, and gastric cancers, 5-10% of bladder, cervical, pancreas, and uterine cancers, and 1-5% of colorectal, lung, and ovarian cancers^{6,7,94,95,96,97,98,99}. Recurrent somatic activating mutations in ERBB2/HER2 occur at low frequencies (<1%) in diverse cancer types^{6,100,101}. In breast, bladder, and colorectal cancers, the most common recurrent ERBB2 activating mutations include kinase domain mutations L755S and V777L and the extracellular domain mutation S310F. In lung cancer, the most common recurrent ERBB2 activating mutations include in-frame exon 20 insertions, particularly Y772_A775dup.

Potential relevance: The discovery of ERBB2/HER2 as an important driver of breast cancer in 1987 led to the development of trastuzumab, a humanized monoclonal antibody with specificity to the extracellular domain of HER2^{102,103}. Trastuzumab¹⁰⁴ was FDA approved for the treatment of HER2 positive breast cancer in 1998, and subsequently in HER2 positive metastatic gastric and gastroesophageal junction adenocarcinoma in 2010. Additional monoclonal antibody therapies have been approved by the FDA for HER2-positive breast cancer including pertuzumab¹⁰⁵ (2012), a humanized monoclonal antibody that inhibits HER2 dimerization, and ado-trastuzumab emtansine¹⁰⁶ (2013), a conjugate of trastuzumab and a potent antimicrotubule agent. The combination of pertuzumab, trastuzumab, and a taxane is the preferred front-line regimen for HER2-positive metastatic breast cancer⁴³. In addition to monoclonal antibodies, the small molecule inhibitor lapatinib¹⁰⁷, with specificity for both EGFR and ERBB2, was FDA approved (2007) for the treatment of patients with advanced HER2-positive breast cancer who have received prior therapy including trastuzumab. In 2017, the FDA approved the use of neratinib¹⁰⁸, an irreversible kinase inhibitor of EGFR, ERBB2/HER2, and ERBB4, for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer. In 2020, the FDA approved neratinib¹⁰⁸ in combination with capecitabine for HER2-positive advanced or metastatic patients after two or more prior HER2-directed therapies. Also in 2020, the TKI irbinitinib¹⁰⁹ was FDA approved for HER2 overexpressing or amplified breast cancer in combination with trastuzumab and capecitabine. In 2021, the PD-1 blocking antibody, pembrolizumab, in combination with trastuzumab, fluoropyrimidine- and platinum-based chemotherapy, was approved for HER2 amplified gastric or gastroesophageal (GEJ) adenocarcinoma in the first line⁸⁰. In 2024, a bispecific HER2 antibody, zanidatamab¹¹⁰, was approved for the treatment of adults with previously treated, unresectable or metastatic ERBB2 overexpressing biliary tract cancer. The vaccine, nelipepimut-S¹¹¹, was

Biomarker Descriptions (continued)

granted fast track designation by the FDA (2016) in patients with low to intermediate HER2 expressing (IHC score 1+ or 2+) breast cancer. In 2018 fast track designation was granted to the monoclonal antibody margetuximab¹¹² in patients with ERBB2 positive breast cancer previously treated with an anti-HER2 therapy. In 2019, fast track designation was granted to the HER2-targeting antibody drug conjugate, amcenestrant¹¹³, for HER2-positive advanced or metastatic breast cancer after one or more prior anti-HER2 based regimens. Additionally, in 2019, zanidatamab¹¹⁴, received fast track designation in combination with standard chemotherapy for patients with HER2-overexpressing gastroesophageal adenocarcinoma (GEA). In 2020, BDTX-189¹¹⁵ received fast track designation for adult patients with solid tumors harboring an allosteric human ERBB2 mutation or exon 20 insertion, and the humanized anti-HER2 antibody drug conjugate disitamab vedotin received breakthrough designation for adult patients with HER2-positive urothelial cancer after previous platinum-chemotherapy treatment¹¹⁶. In 2021, the antibody-drug conjugate ARX788¹¹⁷ received fast track designation as a monotherapy for advanced or metastatic HER2-positive breast cancer that have progressed on one or more anti-HER2 regimens. Additionally, fast track designation was granted to HER2-targeted chimeric antigen receptor macrophage (CAR-M) (2019), CT-0508¹¹⁸, and to ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy (2024), CT-0525¹¹⁹, for HER2-overexpressing solid tumors. In 2024, a small molecule inhibitor, BAY-2927088¹²⁰, received breakthrough designation for the treatment of NSCLC patients with ERBB2 activating mutations. Certain activating mutations have been observed to impart sensitivity to neratinib, afatinib, lapatinib, and trastuzumab, or dacomitinib in early and ongoing clinical studies^{121,122,123,124,125}. ERBB2 kinase domain mutations R896G and V659E both showed response to afatinib in two NSCLC case studies^{126,127}. Additionally, acquired HER2 mutations in estrogen receptor-positive (ER+) breast cancer have been shown to confer resistance to hormone therapy¹²⁸. However, this was shown to be overcome by neratinib in combination with therapies targeting ER¹²⁸. Additionally, in 2024, FDA granted fast track designation to zongertinib¹²⁹, an irreversible ERBB2 tyrosine kinase inhibitor, for HER2-mutant NSCLC tumors that have progressed on or after platinum-based therapy.

TP53 p.(R175H) c.524G>A

tumor protein p53

Background: The TP53 gene encodes the tumor suppressor protein p53, which binds to DNA and activates transcription in response to diverse cellular stresses to induce cell cycle arrest, apoptosis, or DNA repair¹. In unstressed cells, TP53 is kept inactive by targeted degradation via MDM2, a substrate recognition factor for ubiquitin-dependent proteolysis². Alterations in TP53 are required for oncogenesis as they result in loss of protein function and gain of transforming potential³. Germline mutations in TP53 are the underlying cause of Li-Fraumeni syndrome, a complex hereditary cancer predisposition disorder associated with early-onset cancers^{4,5}.

Alterations and prevalence: TP53 is the most frequently mutated gene in the cancer genome with approximately half of all cancers experiencing TP53 mutations. Ovarian, head and neck, esophageal, and lung squamous cancers have particularly high TP53 mutation rates (60-90%)^{6,7,8,9,10,11}. Approximately two-thirds of TP53 mutations are missense mutations and several recurrent missense mutations are common, including substitutions at codons R158, R175, Y220, R248, R273, and R282^{6,7}. Invariably, recurrent missense mutations in TP53 inactivate its ability to bind DNA and activate transcription of target genes^{12,13,14,15}. Alterations in TP53 are also observed in pediatric cancers^{6,7}. Somatic mutations are observed in 53% of non-Hodgkin lymphoma, 24% of soft tissue sarcoma, 19% of glioma, 13% of bone cancer, 9% of B-lymphoblastic leukemia/lymphoma, 4% of embryonal tumors, 3% of Wilms tumor and leukemia, 2% of T-lymphoblastic leukemia/lymphoma, and less than 1% of peripheral nervous system cancers (5 in 1158 cases)^{6,7}. Biallelic loss of TP53 is observed in 10% of bone cancer, 2% of Wilms tumor, and less than 1% of B-lymphoblastic leukemia/lymphoma (2 in 731 cases) and leukemia (1 in 250 cases)^{6,7}.

Potential relevance: The small molecule p53 reactivator, PC14586¹⁶ (2020), received a fast track designation by the FDA for advanced tumors harboring a TP53 Y220C mutation. The FDA has granted fast track designation to the p53 reactivator, eprenetapopt¹⁷, (2019) and breakthrough designation¹⁸ (2020) in combination with azacitidine or azacitidine and venetoclax for acute myeloid leukemia patients (AML) and myelodysplastic syndrome (MDS) harboring a TP53 mutation, respectively. In addition to investigational therapies aimed at restoring wild-type TP53 activity, compounds that induce synthetic lethality are also under clinical evaluation^{19,20}. TP53 mutation are a diagnostic marker of SHH-activated, TP53-mutant medulloblastoma²¹. TP53 mutations confer poor prognosis and poor risk in multiple blood cancers including AML, MDS, myeloproliferative neoplasms (MPN), and chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL)^{22,23,24,25,26,27}. In mantle cell lymphoma, TP53 mutations are associated with poor prognosis when treated with conventional therapy including hematopoietic cell transplant²⁸. Mono- and bi-allelic mutations in TP53 confer unique characteristics in MDS, with multi-hit patients also experiencing associations with complex karyotype, few co-occurring mutations, and high-risk disease presentation as well as predicted death and leukemic transformation independent of the IPSS-R staging system²⁹.

ESR1 p.(R555H) c.1664G>A

estrogen receptor 1

Background: The ESR1 gene encodes estrogen receptor 1 (ERα), which is a member of the superfamily of nuclear receptors which convert extracellular signals into transcriptional responses. A related gene, ESR2, encodes the cognate ERβ protein. ERα is a ligand-activated transcription factor regulated by the hormone estrogen^{30,31}. Estrogen binding to ERα results in receptor dimerization, nuclear

Biomarker Descriptions (continued)

translocation, and target gene transcription. In addition, estrogen binding to the ERα results in the activation of the RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, cAMP/PKA and PLC/PKC signaling pathways and cell proliferation and survival³².

Alterations and prevalence: Approximately 70% of breast cancers express ERα and ERβ positivity. Mutations in the ERα ligand binding domain, including S463P, Y537S, and D538G, result in endocrine-independent constitutive receptor activation, which is a common mechanism of endocrine resistance^{33,34,35,36}. ESR1 gene fusions and ESR1 copy number gains have also been observed and are associated with advanced endocrine resistant disease^{37,38,39,40,41}.

Potential relevance: The FDA has approved elacestrant⁴² (2023) for the treatment of postmenopausal women or adult men with ER-positive/ERBB2-negative, ESR1-mutated advanced or metastatic breast cancer⁴³. The FDA has also granted fast track designations to the following therapies: AC699⁴⁴ (2024) and lasofoxifene⁴⁵ (2019) for ESR1-mutated, ER-positive/ERBB2-negative metastatic breast cancer, camizaestrant⁴⁶ for ESR1-mutated, HR-positive/ERBB2-negative metastatic breast cancer, and seviteronel⁴⁷ (2016) for ER-positive breast cancer. Anti-estrogen (endocrine) treatments such as tamoxifen⁴⁸ (1977), fulvestrant⁴⁹ (2002), letrozole⁵⁰ (1995), and exemestane⁵¹ (2005) are FDA approved for ER-positive metastatic breast cancers^{52,53}. Although ERα and ERβ positivity predicts response to endocrine therapies, about a quarter of patients with primary breast cancer and almost all patients with metastatic disease will develop endocrine resistance^{54,55,56}.

Microsatellite stable

Background: Microsatellites are short tandem repeats (STR) of 1 to 6 bases of DNA between 5 to 50 repeat units in length. There are approximately 0.5 million STRs that occupy 3% of the human genome⁶⁷. Microsatellite instability (MSI) is defined as a change in the length of a microsatellite in a tumor as compared to normal tissue^{68,69}. MSI is closely tied to the status of the mismatch repair (MMR) genes. In humans, the core MMR genes include MLH1, MSH2, MSH6, and PMS2⁷⁰. Mutations and loss of expression in MMR genes, known as defective MMR (dMMR), lead to MSI. In contrast, when MMR genes lack alterations, they are referred to as MMR proficient (pMMR). Consensus criteria were first described in 1998 and defined MSI-high (MSI-H) as instability in two or more of the following five markers: BAT25, BAT26, D5S346, D2S123, and D17S250⁷¹. Tumors with instability in one of the five markers were defined as MSI-low (MSI-L) whereas, those with instability in zero markers were defined as MS-stable (MSS)⁷¹. Tumors classified as MSI-L are often phenotypically indistinguishable from MSS tumors and tend to be grouped with MSS^{72,73,74,75,76}. MSI-H is a hallmark of Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer, which is caused by germline mutations in the MMR genes⁶⁹. LS is associated with an increased risk of developing colorectal cancer, as well as other cancers, including endometrial and stomach cancer^{68,69,73,77}.

Alterations and prevalence: The MSI-H phenotype is observed in 30% of uterine corpus endothelial carcinoma, 20% of stomach adenocarcinoma, 15-20% of colon adenocarcinoma, and 5-10% of rectal adenocarcinoma^{68,69,78,79}. MSI-H is also observed in 5% of adrenal cortical carcinoma and at lower frequencies in other cancers such as esophageal, liver, and ovarian cancers^{78,79}.

Potential relevance: Anti-PD-1 immune checkpoint inhibitors including pembrolizumab⁸⁰ (2014) and nivolumab⁸¹ (2015) are approved for patients with MSI-H or dMMR colorectal cancer who have progressed following chemotherapy. Pembrolizumab⁸⁰ is also approved as a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR with disease progression on prior therapy who are not candidates for surgery or radiation. Importantly, pembrolizumab is approved for the treatment of MSI-H or dMMR solid tumors that have progressed following treatment, with no alternative option and is the first anti-PD-1 inhibitor to be approved with a tumor agnostic indication⁸⁰. Dostarlimab⁸² (2021) is also approved for dMMR recurrent or advanced endometrial carcinoma or solid tumors that have progressed on prior treatment and is recommended as a subsequent therapy option in dMMR/MSI-H advanced or metastatic colon or rectal cancer^{74,83}. The cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody, ipilimumab⁸⁴ (2011), is approved alone or in combination with nivolumab in MSI-H or dMMR colorectal cancer that has progressed following treatment with chemotherapy. MSI-H may confer a favorable prognosis in colorectal cancer although outcomes vary depending on stage and tumor location^{74,85,86}. Specifically, MSI-H is a strong prognostic indicator of better overall survival (OS) and relapse free survival (RFS) in stage II as compared to stage III colorectal cancer patients⁸⁶. The majority of patients with tumors classified as either MSS or pMMR do not benefit from treatment with single-agent immune checkpoint inhibitors as compared to those with MSI-H tumors^{87,88}. However, checkpoint blockade with the addition of chemotherapy or targeted therapies have demonstrated response in MSS or pMMR cancers^{87,88}.

ZFHX3 p.(S1644*) c.4929_4929delCinsTT

zinc finger homeobox 3

Background: ZFHX3 encodes zinc finger homeobox 3, a large transcription factor composed of several DNA binding domains, including seventeen zinc finger domains and four homeodomains^{1,57,58}. Functionally, ZFHX3 is found to be necessary for neuronal and myogenic differentiation^{58,59}. ZFHX3 is capable of binding and repressing transcription of α-fetoprotein (AFP), thereby negatively regulating the expression of MYB and cancer cell growth^{60,61,62,63,64}. In addition, ZFHX3 has been observed to be altered in several cancer types, supporting a tumor suppressor role for ZFHX3^{60,63,65,66}.

Biomarker Descriptions (continued)

Alterations and prevalence: Somatic mutations in ZFHX3 are observed in 24% of uterine corpus endometrial carcinoma, 14% of skin cutaneous melanoma, 10% of colorectal adenocarcinoma, 9% of stomach adenocarcinoma, 8% of lung squamous cell carcinoma, 6% of cervical squamous cell carcinoma, 5% of uterine carcinosarcoma, bladder urothelial carcinoma, and lung adenocarcinoma, 3% of head and neck squamous cell carcinoma, adrenocortical carcinoma, cholangiocarcinoma, esophageal adenocarcinoma, and prostate adenocarcinoma, and 2% of diffuse large B-cell lymphoma, glioblastoma multiforme, pancreatic adenocarcinoma, liver hepatocellular carcinoma, thyroid carcinoma, breast invasive carcinoma, ovarian serous cystadenocarcinoma, thymoma, sarcoma, and acute myeloid leukemia^{6,7}. Biallelic loss of ZFHX3 is observed in 6% of prostate adenocarcinoma, 4% of uterine carcinosarcoma, 3% of ovarian serous cystadenocarcinoma, and 2% of uterine corpus endometrial carcinoma, breast invasive carcinoma, and esophageal adenocarcinoma^{6,7}.

Potential relevance: Currently, no therapies are approved for ZFHX3 aberrations.

ERBB2 amplification (continued)

A CT-0525

Cancer type: Solid Tumor

Variant class: ERBB2 overexpression

Supporting Statement:

The FDA has granted Fast Track designation to the ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy, CT-0525, for the treatment of patients with human epidermal growth factor receptor 2 (HER2) overexpressing solid tumours.

Reference:

<https://www.prnewswire.com/news-releases/carisma-therapeutics-granted-fda-fast-track-designation-for-ct-0525-for-the-treatment-of-her2overexpressing-solid-tumors-302180804.html>

A zanidatamab + chemotherapy

Cancer type: Gastroesophageal Junction Adenocarcinoma

Variant class: ERBB2 overexpression

Supporting Statement:

The FDA has granted Fast Track designation to the HER2 targeted bispecific antibody, zanidatamab, for HER2-overexpressing gastroesophageal adenocarcinoma (GEA) to be used in combination with standard-of-care chemotherapy.

Reference:

<https://www.targetedonc.com/view/her2targeted-antibody-zw25-earns-fda-fast-track-designation-in-gea>

A anvatabart opadotin

Cancer type: Breast Cancer

Variant class: ERBB2 positive

Supporting Statement:

The FDA has granted Fast Track designation to the HER2-targeting antibody drug conjugate, anvatabart opadotin (ARX-788), for HER2-positive metastatic breast cancer.

Reference:

<https://ir.ambrx.com/news/news-details/2023/ACE-Breast-02-Pivotal-Phase-3-Study-of-Ambrxs-ARX788-for-the-Treatment-of-HER2-Positive-Metastatic-Breast-Cancer-Achieves-Positive-Results/default.aspx>

A CYNK-101 + pembrolizumab + trastuzumab + chemotherapy

Cancer type: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

Variant class: ERBB2 positive

Supporting Statement:

The FDA has granted Fast Track designation to the genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-101, in combination with standard chemotherapy, trastuzumab, and pembrolizumab for the treatment of HER2/neu positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Reference:

<https://celularity.com/celularity-receives-fast-track-designation-from-u-s-fda-for-its-nk-cell-therapy-cynk-101/>

ERBB2 amplification (continued)

evorpacept

Cancer type: Gastric Cancer,
Gastroesophageal Junction Adenocarcinoma

Variant class: ERBB2 positive

Supporting Statement:

The FDA has granted Fast Track designation to the CD47 checkpoint inhibitor, ALX148, for the second-line treatment of patients with HER2-positive gastric or gastroesophageal junction carcinoma.

Reference:

<https://www.targetedonc.com/view/two-fda-fast-track-designations-granted-to-alx148-for-hnsc-and-gastric-gcj-adenocarcinomas>

Current ESMO Information

 Contraindicated  Not recommended  Resistance  Breakthrough  Fast Track

ESMO information is current as of 2025-04-01. For the most up-to-date information, search www.esmo.org.

ERBB2 amplification

trastuzumab

Cancer type: Gastric Cancer

Variant class: ERBB2 overexpression

Summary:

ESMO Clinical Practice Guidelines include the following supporting statement:

- "Treatment with trastuzumab is not recommended after first-line therapy in HER2-positive advanced gastric cancer [I, D]."

Reference: ESMO Clinical Practice Guidelines - ESMO-Gastric Cancer [Ann Oncol (2022), doi: <https://doi.org/10.1016/j.annonc.2022.07.004>.]

hormone therapy

Cancer type: Breast Cancer

Variant class: ERBB2 positive

Other criteria: Hormone receptor positive

ESMO Level of Evidence/Grade of Recommendation: III / C

Summary:

ESMO™ Clinical Practice Guidelines include the following supporting statement:

- "The use of single-agent ET without a HER2-targeted therapy is not routinely recommended unless cardiac disease precludes the safe use of HER2-directed therapies [III, C]"

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Breast Cancer [Ann Oncol (2021) VOLUME 32, ISSUE 12, P1475-1495, DECEMBER 01, 2021; DOI:<https://doi.org/10.1016/j.annonc.2021.09.019>]

Genes Assayed

Genes Assayed for the Detection of DNA Sequence Variants

ABL1, ABL2, ACVR1, AKT1, AKT2, AKT3, ALK, AR, ARAF, ATP1A1, AURKA, AURKB, AURKC, AXL, BCL2, BCL2L12, BCL6, BCR, BMP5, BRAF, BTK, CACNA1D, CARD11, CBL, CCND1, CCND2, CCND3, CCNE1, CD79B, CDK4, CDK6, CHD4, CSF1R, CTNNB1, CUL1, CYSLTR2, DDR2, DGCR8, DROSHA, E2F1, EGFR, EIF1AX, EPAS1, ERBB2, ERBB3, ERBB4, ESR1, EZH2, FAM135B, FGF7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXA1, FOXL2, FOXO1, GATA2, GLI1, GNA11, GNAQ, GNAS, HIF1A, HRAS, IDH1, IDH2, IKBKB, IL6ST, IL7R, IRF4, IRS4, KCNJ5, KDR, KIT, KLF4, KLF5, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAPK1, MAX, MDM4, MECOM, MED12, MEF2B, MET, MITF, MPL, MTOR, MYC, MYCN, MYD88, MYO10, NFE2L2, NRAS, NSD2, NT5C2, NTRK1, NTRK2, NTRK3, NUP93, PAX5, PCBP1, PDGFRA, PDGFRB, PIK3C2B, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R2, PIM1, PLCG1, PPP2R1A, PPP6C, PRKACA, PTPN11, PTPRD, PXDNL, RAC1, RAF1, RARA, RET, RGS7, RHEB, RHOA, RICTOR, RIT1, ROS1, RPL10, SETBP1, SF3B1, SIX1, SIX2, SLC01B3, SMC1A, SMO, SNCAIP, SOS1, SOX2, SPOP, SRC, SRSF2, STAT3, STAT5B, STAT6, TAF1, TERT, TGFB1, TOP1, TOP2A, TPMT, TRRAP, TSHR, U2AF1, USP8, WAS, XPO1, ZNF217, ZNF429

Genes Assayed for the Detection of Copy Number Variations

ABCB1, ABL1, ABL2, ABRAXAS1, ACVR1B, ACVR2A, ADAMTS12, ADAMTS2, AKT1, AKT2, AKT3, ALK, AMER1, APC, AR, ARAF, ARHGAP35, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AURKA, AURKC, AXIN1, AXIN2, AXL, B2M, BAP1, BARD1, BCL2, BCL2L12, BCL6, BCOR, BLM, BMPR2, BRAF, BRCA1, BRCA2, BRIP1, CARD11, CASP8, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD276, CDC73, CDH1, CDH10, CDK12, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHD4, CHEK1, CHEK2, CIC, CREBBP, CSMD3, CTCF, CTLA4, CTNND2, CUL3, CUL4A, CUL4B, CYLD, CYP2C9, DAXX, DDR1, DDR2, DDX3X, DICER1, DNMT3A, DOCK3, DPYD, DSC1, DSC3, EGFR, EIF1AX, ELF3, EMSY, ENO1, EP300, EPCAM, EPHA2, ERAP1, ERAP2, ERBB2, ERBB3, ERBB4, ERCC2, ERCC4, ERFF1, ESR1, ETV6, EZH2, FAM135B, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAT1, FBXW7, FGF19, FGF23, FGF3, FGF4, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXA1, FUBP1, FYN, GATA2, GATA3, GLI3, GNA13, GNAS, GPS2, HDAC2, HDAC9, HLA-A, HLA-B, HNF1A, IDH2, IGF1R, IKBKB, IL7R, INPP4B, JAK1, JAK2, JAK3, KDM5C, KDM6A, KDR, KEAP1, KIT, KLF5, KMT2A, KMT2B, KMT2C, KMT2D, KRAS, LARP4B, LATS1, LATS2, MAGOH, MAP2K1, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK1, MAPK8, MAX, MCL1, MDM2, MDM4, MECOM, MEF2B, MEN1, MET, MGA, MITF, MLH1, MLH3, MPL, MRE11, MSH2, MSH3, MSH6, MTAP, MTOR, MUTYH, MYC, MYCL, MYCN, MYD88, NBN, NCOR1, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NRAS, NTRK1, NTRK3, PALB2, PARP1, PARP2, PARP3, PARP4, PBRM1, PCBP1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDIA3, PGD, PHF6, PIK3C2B, PIK3CA, PIK3CB, PIK3R1, PIK3R2, PIM1, PLCG1, PMS1, PMS2, POLD1, POLE, POT1, PPM1D, PPP2R1A, PPP2R2A, PPP6C, PRDM1, PRDM9, PRKACA, PRKAR1A, PTCH1, PTEN, PTPN11, PTPRT, PXDNL, RAC1, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RARA, RASA1, RASA2, RB1, RBM10, RECQL4, RET, RHEB, RICTOR, RIT1, RNASEH2A, RNASEH2B, RNF43, ROS1, RPA1, RPS6KB1, RPTOR, RUNX1, SDHA, SDHB, SDHD, SETBP1, SETD2, SF3B1, SLC01B3, SLX4, SMAD2, SMAD4, SMARCA4, SMARCB1, SMC1A, SMO, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STAT6, STK11, SUFU, TAP1, TAP2, TBX3, TCF7L2, TERT, TET2, TGFB2, TNFAIP3, TNFRSF14, TOP1, TP53, TP63, TPMT, TPP2, TSC1, TSC2, U2AF1, USP8, USP9X, VHL, WT1, XPO1, XRCC2, XRCC3, YAP1, YES1, ZFH3, ZMYM3, ZNF217, ZNF429, ZRSR2

Genes Assayed for the Detection of Fusions

AKT2, ALK, AR, AXL, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PPARG, PRKACA, PRKACB, PTEN, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSP02, RSP03, TERT

Genes Assayed with Full Exon Coverage

ABRAXAS1, ACVR1B, ACVR2A, ADAMTS12, ADAMTS2, AMER1, APC, ARHGAP35, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AXIN1, AXIN2, B2M, BAP1, BARD1, BCOR, BLM, BMPR2, BRCA1, BRCA2, BRIP1, CALR, CASP8, CBFB, CD274, CD276, CDC73, CDH1, CDH10, CDK12, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHEK1, CHEK2, CIC, CIITA, CREBBP, CSMD3, CTCF, CTLA4, CUL3, CUL4A, CUL4B, CYLD, CYP2C9, CYP2D6, DAXX, DDX3X, DICER1, DNMT3A, DOCK3, DPYD, DSC1, DSC3, ELF3, ENO1, EP300, EPCAM, EPHA2, ERAP1, ERAP2, ERCC2, ERCC4, ERCC5, ERFF1, ETV6, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAS, FAT1, FBXW7, FUBP1, GATA3, GNA13, GPS2, HDAC2, HDAC9, HLA-A, HLA-B, HNF1A, ID3, INPP4B, JAK1, JAK2, JAK3, KDM5C, KDM6A, KEAP1, KLHL13, KMT2A, KMT2B, KMT2C, KMT2D, LARP4B, LATS1, LATS2, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK8, MEN1, MGA, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MTAP, MTUS2, MUTYH, NBN, NCOR1, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, NOTCH4, PALB2, PARP1, PARP2, PARP3, PARP4, PBRM1, PDCD1, PDCD1LG2, PDIA3, PGD, PHF6, PIK3R1, PMS1, PMS2, POLD1, POLE, POT1, PPM1D, PPP2R2A, PRDM1, PRDM9, PRKAR1A, PSMB10, PSMB8, PSMB9, PTCH1, PTEN, PTPRT, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RASA1, RASA2, RB1, RBM10, RECQL4, RNASEH2A, RNASEH2B, RNASEH2C, RNF43, RPA1, RPL22, RPL5, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SETD2, SLX4, SMAD2, SMAD4, SMARCA4, SMARCB1, SOCS1, SOX9, SPEN, STAG2, STAT1, STK11, SUFU, TAP1, TAP2, TBX3, TCF7L2, TET2, TGFB2, TMEM132D, TNFAIP3, TNFRSF14, TP53, TP63, TPP2, TSC1, TSC2, UGT1A1, USP9X, VHL, WT1, XRCC2, XRCC3, ZBTB20, ZFH3, ZMYM3, ZRSR2

Relevant Therapy Summary

● In this cancer type
 ○ In other cancer type
 ① In this cancer type and other cancer types
 ✕ No evidence

ERBB2 amplification

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
trastuzumab deruxtecan	①	①	○	○	● (II)
ado-trastuzumab emtansine	○	○	○	○	● (II)
lapatinib + capecitabine	○	○	○	○	✕
neratinib	○	○	○	○	✕
pertuzumab + trastuzumab + chemotherapy	○	○	○	○	✕
pertuzumab + trastuzumab + docetaxel	○	○	○	○	✕
trastuzumab + docetaxel	○	○	○	○	✕
trastuzumab + paclitaxel	○	○	○	○	✕
trastuzumab + tucatinib + capecitabine	○	○	○	○	✕
trastuzumab	○	○	○	✕	● (II)
trastuzumab + capecitabine + cisplatin	○	○	○	✕	✕
trastuzumab + carboplatin + docetaxel	○	○	○	✕	✕
trastuzumab + cisplatin + fluorouracil	○	○	○	✕	✕
zanidatamab	○	○	✕	○	● (II)
neratinib + capecitabine	○	○	✕	✕	✕
trastuzumab + tucatinib	○	○	✕	✕	✕
lapatinib + letrozole	○	✕	○	✕	✕
pembrolizumab + trastuzumab + chemotherapy + fluoropyrimidine	○	✕	○	✕	✕
pertuzumab/trastuzumab/hyaluronidase-zzxf + cyclophosphamide + doxorubicin	○	✕	○	✕	✕
pertuzumab/trastuzumab/hyaluronidase-zzxf + docetaxel	○	✕	○	✕	✕
trastuzumab (Biocon)	○	✕	○	✕	✕
trastuzumab (Biocon) + capecitabine + cisplatin	○	✕	○	✕	✕
trastuzumab (Biocon) + carboplatin + docetaxel	○	✕	○	✕	✕
trastuzumab (Biocon) + cisplatin + fluorouracil	○	✕	○	✕	✕
trastuzumab (Biocon) + docetaxel	○	✕	○	✕	✕
trastuzumab (Biocon) + paclitaxel	○	✕	○	✕	✕
trastuzumab (Celltrion)	○	✕	○	✕	✕

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type
 ○ In other cancer type
 ⓘ In this cancer type and other cancer types
 ✕ No evidence

ERBB2 amplification (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
trastuzumab (Celltrion) + capecitabine + cisplatin	○	✕	○	✕	✕
trastuzumab (Celltrion) + carboplatin + docetaxel	○	✕	○	✕	✕
trastuzumab (Celltrion) + cisplatin + fluorouracil	○	✕	○	✕	✕
trastuzumab (Celltrion) + docetaxel	○	✕	○	✕	✕
trastuzumab (Celltrion) + paclitaxel	○	✕	○	✕	✕
trastuzumab (Henlius)	○	✕	○	✕	✕
trastuzumab (Pfizer)	○	✕	○	✕	✕
trastuzumab (Pfizer) + capecitabine + cisplatin	○	✕	○	✕	✕
trastuzumab (Pfizer) + carboplatin + docetaxel	○	✕	○	✕	✕
trastuzumab (Pfizer) + cisplatin + fluorouracil	○	✕	○	✕	✕
trastuzumab (Pfizer) + docetaxel	○	✕	○	✕	✕
trastuzumab (Pfizer) + paclitaxel	○	✕	○	✕	✕
trastuzumab (Samsung Bioepis)	○	✕	○	✕	✕
trastuzumab (Samsung Bioepis) + capecitabine + cisplatin	○	✕	○	✕	✕
trastuzumab (Samsung Bioepis) + carboplatin + docetaxel	○	✕	○	✕	✕
trastuzumab (Samsung Bioepis) + cisplatin + fluorouracil	○	✕	○	✕	✕
trastuzumab (Samsung Bioepis) + docetaxel	○	✕	○	✕	✕
trastuzumab (Samsung Bioepis) + paclitaxel	○	✕	○	✕	✕
trastuzumab (Synthon)	○	✕	○	✕	✕
trastuzumab (Synthon) + capecitabine + cisplatin	○	✕	○	✕	✕
trastuzumab (Synthon) + carboplatin + docetaxel	○	✕	○	✕	✕
trastuzumab (Synthon) + cisplatin + fluorouracil	○	✕	○	✕	✕
trastuzumab (Synthon) + docetaxel	○	✕	○	✕	✕
trastuzumab (Synthon) + paclitaxel	○	✕	○	✕	✕
margetuximab + chemotherapy	○	✕	✕	○	✕
trastuzumab and hyaluronidase-oysk	○	✕	✕	✕	✕
trastuzumab and hyaluronidase-oysk + carboplatin + docetaxel	○	✕	✕	✕	✕

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type
 ○ In other cancer type
 ① In this cancer type and other cancer types
 ✕ No evidence

ERBB2 amplification (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
trastuzumab and hyaluronidase-oysk + docetaxel	○	✕	✕	✕	✕
trastuzumab and hyaluronidase-oysk + paclitaxel	○	✕	✕	✕	✕
lapatinib + trastuzumab	✕	○	○	○	✕
pertuzumab + trastuzumab	✕	○	✕	○	● (II/III)
pertuzumab + trastuzumab + hormone therapy	✕	○	✕	○	✕
pertuzumab + trastuzumab + paclitaxel	✕	○	✕	○	✕
trastuzumab + chemotherapy	✕	○	✕	○	✕
trastuzumab + hormone therapy	✕	○	✕	○	✕
abemaciclib + trastuzumab + fulvestrant	✕	○	✕	✕	✕
aromatase inhibitor	✕	○	✕	✕	✕
fulvestrant	✕	○	✕	✕	✕
hormone therapy	✕	○	✕	✕	✕
lapatinib + aromatase inhibitor	✕	○	✕	✕	✕
lapatinib + trastuzumab + aromatase inhibitor	✕	○	✕	✕	✕
margetuximab + capecitabine	✕	○	✕	✕	✕
margetuximab + eribulin	✕	○	✕	✕	✕
margetuximab + gemcitabine	✕	○	✕	✕	✕
margetuximab + vinorelbine	✕	○	✕	✕	✕
neratinib + paclitaxel	✕	○	✕	✕	✕
pembrolizumab + trastuzumab + capecitabine + cisplatin	✕	○	✕	✕	✕
pembrolizumab + trastuzumab + capecitabine + oxaliplatin	✕	○	✕	✕	✕
pembrolizumab + trastuzumab + cisplatin + fluorouracil	✕	○	✕	✕	✕
pembrolizumab + trastuzumab + fluorouracil + oxaliplatin	✕	○	✕	✕	✕
pertuzumab + trastuzumab + carboplatin + docetaxel	✕	○	✕	✕	✕
pertuzumab + trastuzumab + carboplatin + paclitaxel	✕	○	✕	✕	✕
pertuzumab + trastuzumab + hormone therapy + chemotherapy	✕	○	✕	✕	✕

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

 In this cancer type
  In other cancer type
  In this cancer type and other cancer types
  No evidence

ERBB2 amplification (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
tamoxifen	×	○	×	×	×
trastuzumab + aromatase inhibitor	×	○	×	×	×
trastuzumab + capecitabine	×	○	×	×	×
trastuzumab + capecitabine + oxaliplatin	×	○	×	×	×
trastuzumab + carboplatin + paclitaxel	×	○	×	×	×
trastuzumab + chemotherapy (non-anthracycline)	×	○	×	×	×
trastuzumab + cisplatin + docetaxel	×	○	×	×	×
trastuzumab + cisplatin + docetaxel + fluorouracil	×	○	×	×	×
trastuzumab + cisplatin + paclitaxel	×	○	×	×	×
trastuzumab + cyclophosphamide + docetaxel	×	○	×	×	×
trastuzumab + docetaxel + fluorouracil + oxaliplatin	×	○	×	×	×
trastuzumab + fluorouracil	×	○	×	×	×
trastuzumab + fluorouracil + irinotecan	×	○	×	×	×
trastuzumab + fluorouracil + oxaliplatin	×	○	×	×	×
trastuzumab + fulvestrant	×	○	×	×	×
trastuzumab + hormone therapy + chemotherapy	×	○	×	×	×
trastuzumab + tamoxifen	×	○	×	×	×
trastuzumab + vinorelbine	×	○	×	×	×
pertuzumab/trastuzumab/hyaluronidase-zzxf + carboplatin + docetaxel	×	×	○	×	×
pertuzumab/trastuzumab/hyaluronidase-zzxf + cyclophosphamide + doxorubicin + fluorouracil	×	×	○	×	×
pertuzumab/trastuzumab/hyaluronidase-zzxf + cyclophosphamide + epirubicin	×	×	○	×	×
pertuzumab/trastuzumab/hyaluronidase-zzxf + paclitaxel	×	×	○	×	×
trastuzumab (Biocon) + anastrozole	×	×	○	×	×
trastuzumab (Celltrion) + anastrozole	×	×	○	×	×
trastuzumab (EirGenix)	×	×	○	×	×
trastuzumab (EirGenix) + anastrozole	×	×	○	×	×
trastuzumab (EirGenix) + capecitabine + cisplatin	×	×	○	×	×

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type
 ○ In other cancer type
 ⓘ In this cancer type and other cancer types
 ✕ No evidence

ERBB2 amplification (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
trastuzumab (EirGenix) + carboplatin + docetaxel	✕	✕	○	✕	✕
trastuzumab (EirGenix) + cisplatin + fluorouracil	✕	✕	○	✕	✕
trastuzumab (EirGenix) + docetaxel	✕	✕	○	✕	✕
trastuzumab (EirGenix) + paclitaxel	✕	✕	○	✕	✕
trastuzumab (Henlius) + anastrozole	✕	✕	○	✕	✕
trastuzumab (Henlius) + capecitabine + cisplatin	✕	✕	○	✕	✕
trastuzumab (Henlius) + carboplatin + docetaxel	✕	✕	○	✕	✕
trastuzumab (Henlius) + cisplatin + fluorouracil	✕	✕	○	✕	✕
trastuzumab (Henlius) + docetaxel	✕	✕	○	✕	✕
trastuzumab (Henlius) + paclitaxel	✕	✕	○	✕	✕
trastuzumab (Pfizer) + anastrozole	✕	✕	○	✕	✕
trastuzumab (Prestige BioPharma)	✕	✕	○	✕	✕
trastuzumab (Prestige BioPharma) + anastrozole	✕	✕	○	✕	✕
trastuzumab (Prestige BioPharma) + capecitabine + cisplatin	✕	✕	○	✕	✕
trastuzumab (Prestige BioPharma) + carboplatin + docetaxel	✕	✕	○	✕	✕
trastuzumab (Prestige BioPharma) + cisplatin + fluorouracil	✕	✕	○	✕	✕
trastuzumab (Prestige BioPharma) + docetaxel	✕	✕	○	✕	✕
trastuzumab (Prestige BioPharma) + paclitaxel	✕	✕	○	✕	✕
trastuzumab (Samsung Bioepis) + anastrozole	✕	✕	○	✕	✕
trastuzumab (Synthon) + anastrozole	✕	✕	○	✕	✕
trastuzumab + anastrozole	✕	✕	○	✕	✕
ado-trastuzumab emtansine + hormone therapy	✕	✕	✕	○	✕
lapatinib + hormone therapy	✕	✕	✕	○	✕
lapatinib + trastuzumab + hormone therapy	✕	✕	✕	○	✕
margetuximab	✕	✕	✕	○	✕
neratinib + chemotherapy	✕	✕	✕	○	✕
pertuzumab + trastuzumab + nab-paclitaxel	✕	✕	✕	○	✕
pyrotinib	✕	✕	✕	✕	● (IV)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type
 ○ In other cancer type
 ① In this cancer type and other cancer types
 ✕ No evidence

ERBB2 amplification (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
IAH-0968, chemotherapy	✕	✕	✕	✕	● (III)
allitinib	✕	✕	✕	✕	● (II)
disitamab vedotinaide, tislelizumab, bevacizumab	✕	✕	✕	✕	● (II)
FDA022-BB05	✕	✕	✕	✕	● (II)
neratinib, neratinib + palbociclib	✕	✕	✕	✕	● (II)
pertuzumab + trastuzumab, atezolizumab + pertuzumab/trastuzumab/hyaluronidase-zzxf, trastuzumab + tucatinib	✕	✕	✕	✕	● (II)
pyrotinib, chemotherapy	✕	✕	✕	✕	● (II)
trastuzumab (Samsung Bioepis), chemotherapy	✕	✕	✕	✕	● (II)
tucatinib, ado-trastuzumab emtansine	✕	✕	✕	✕	● (II)
tucatinib, trastuzumab	✕	✕	✕	✕	● (II)
zongertinib	✕	✕	✕	✕	● (II)
AZD-9574, trastuzumab deruxtecan	✕	✕	✕	✕	● (I/II)
BAT-8010, BAT-1006	✕	✕	✕	✕	● (I/II)
BL-M07D1	✕	✕	✕	✕	● (I/II)
DF-1001, nivolumab	✕	✕	✕	✕	● (I/II)
DF-1001, sacituzumab govitecan	✕	✕	✕	✕	● (I/II)
disitamab vedotinaide, catequentinib	✕	✕	✕	✕	● (I/II)
E01001	✕	✕	✕	✕	● (I/II)
HypoSti.CART-HER2, chemotherapy	✕	✕	✕	✕	● (I/II)
IAH-0968	✕	✕	✕	✕	● (I/II)
IBI-354	✕	✕	✕	✕	● (I/II)
JIN-A-04	✕	✕	✕	✕	● (I/II)
JSKN-003	✕	✕	✕	✕	● (I/II)
JSKN-033	✕	✕	✕	✕	● (I/II)
ST-1703	✕	✕	✕	✕	● (I/II)
trastuzumab deruxtecan, neratinib	✕	✕	✕	✕	● (I/II)
trastuzumab pamirtecan, pertuzumab	✕	✕	✕	✕	● (I/II)
YH32367	✕	✕	✕	✕	● (I/II)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

● In this cancer type
 ○ In other cancer type
 ● In this cancer type and other cancer types
 ✕ No evidence

ERBB2 amplification (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
ZV-0203	✕	✕	✕	✕	● (I/II)
177Lu-RAD202	✕	✕	✕	✕	● (I)
ado-trastuzumab emtansine (Shanghai Fosun Pharma)	✕	✕	✕	✕	● (I)
anti-HER-2 MAb (Anke Biotechnology)	✕	✕	✕	✕	● (I)
BC004	✕	✕	✕	✕	● (I)
BL-M17D1	✕	✕	✕	✕	● (I)
BM-230	✕	✕	✕	✕	● (I)
CART-HER2/PD-L1	✕	✕	✕	✕	● (I)
ceralasertib, trastuzumab deruxtecan	✕	✕	✕	✕	● (I)
D3L-001	✕	✕	✕	✕	● (I)
DP-303c	✕	✕	✕	✕	● (I)
DS-1103a, trastuzumab deruxtecan	✕	✕	✕	✕	● (I)
DX126-262	✕	✕	✕	✕	● (I)
ELVN-002, ado-trastuzumab emtansine	✕	✕	✕	✕	● (I)
ELVN-002, trastuzumab	✕	✕	✕	✕	● (I)
ENT-H-1, trastuzumab	✕	✕	✕	✕	● (I)
GQ-1005	✕	✕	✕	✕	● (I)
GQ1001	✕	✕	✕	✕	● (I)
MBS301	✕	✕	✕	✕	● (I)
NC-18	✕	✕	✕	✕	● (I)
NVL-330	✕	✕	✕	✕	● (I)
SPH5030	✕	✕	✕	✕	● (I)
TAS0728	✕	✕	✕	✕	● (I)
TL-938	✕	✕	✕	✕	● (I)
TQB-2102	✕	✕	✕	✕	● (I)
trastuzumab deruxtecan, azenosertib	✕	✕	✕	✕	● (I)
trastuzumab deruxtecan, durvalumab, chemotherapy, volrustomig	✕	✕	✕	✕	● (I)
VVD-159642	✕	✕	✕	✕	● (I)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

In this cancer type

In other cancer type

In this cancer type and other cancer types

No evidence

ERBB2 amplification (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
XMT-2056	×	×	×	×	● (I)
ZN-A-1041, ado-trastuzumab emtansine, trastuzumab deruxtecan, trastuzumab, pertuzumab, pertuzumab/trastuzumab/hyaluronidase-zzxf	×	×	×	×	● (I)

TP53 p.(R175H) c.524G>A

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
CLSP-1025	×	×	×	×	● (I)
NT-175, chemotherapy, aldesleukin	×	×	×	×	● (I)
TP53-EphA-2-CAR-DC, anti-PD-1	×	×	×	×	● (I)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

HRR Details

Gene/Genomic Alteration	Finding
LOH percentage	0.0%
Not Detected	Not Applicable

Homologous recombination repair (HRR) genes were defined from published evidence in relevant therapies, clinical guidelines, as well as clinical trials, and include - BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L.

Thermo Fisher Scientific's Ion Torrent Oncomine Reporter software was used in generation of this report. Software was developed and designed internally by Thermo Fisher Scientific. The analysis was based on Oncomine Reporter (6.1.1 data version 2025.05(007)). The data presented here are from a curated knowledge base of publicly available information, but may not be exhaustive. FDA information was sourced from www.fda.gov and is current as of 2025-04-16. NCCN information was sourced from www.nccn.org and is current as of 2025-04-01. EMA information was sourced from www.ema.europa.eu and is current as of 2025-04-16. ESMO information was sourced from www.esmo.org and is current as of 2025-04-01. Clinical Trials information is current as of 2025-04-01. For the most up-to-date information regarding a particular trial, search www.clinicaltrials.gov by NCT ID or search local clinical trials authority website by local identifier listed in 'Other identifiers.' Variants are reported according to HGVS nomenclature and classified following AMP/ASCO/CAP guidelines (Li et al. 2017). Based on the data sources selected, variants, therapies, and trials listed in this report are listed in order of potential clinical significance but not for predicted efficacy of the therapies.

References

- O'Leary et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. *Nucleic Acids Res.* 2016 Jan 4;44(D1):D733-45. PMID: 26553804
- Nag et al. The MDM2-p53 pathway revisited. *J Biomed Res.* 2013 Jul;27(4):254-71. PMID: 23885265
- Muller et al. Mutant p53 in cancer: new functions and therapeutic opportunities. *Cancer Cell.* 2014 Mar 17;25(3):304-17. PMID: 24651012
- Olivier et al. TP53 mutations in human cancers: origins, consequences, and clinical use. *Cold Spring Harb Perspect Biol.* 2010 Jan;2(1):a001008. PMID: 20182602
- Guha et al. Inherited TP53 Mutations and the Li-Fraumeni Syndrome. *Cold Spring Harb Perspect Med.* 2017 Apr 3;7(4). PMID: 28270529
- Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012 May;2(5):401-4. PMID: 22588877
- Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* 2013 Oct;45(10):1113-20. PMID: 24071849
- Peter et al. Comprehensive genomic characterization of squamous cell lung cancers. *Nature.* 2012 Sep 27;489(7417):519-25. PMID: 22960745
- Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature.* 2015 Jan 29;517(7536):576-82. PMID: 25631445
- Campbell et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. *Nat. Genet.* 2016 Jun;48(6):607-16. PMID: 27158780
- Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. *Nature.* 2017 Jan 12;541(7636):169-175. doi: 10.1038/nature20805. Epub 2017 Jan 4. PMID: 28052061
- Olivier et al. The IARC TP53 database: new online mutation analysis and recommendations to users. *Hum. Mutat.* 2002 Jun;19(6):607-14. PMID: 12007217
- Rivlin et al. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. *Genes Cancer.* 2011 Apr;2(4):466-74. PMID: 21779514
- Petitjean et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. *Oncogene.* 2007 Apr 2;26(15):2157-65. PMID: 17401424
- Soussi et al. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era. *Hum. Mutat.* 2014 Jun;35(6):766-78. PMID: 24729566
- <https://www.globenewswire.com/news-release/2020/10/13/2107498/0/en/PMV-Pharma-Granted-FDA-Fast-Track-Designation-of-PC14586-for-the-Treatment-of-Advanced-Cancer-Patients-that-have-Tumors-with-a-p53-Y220C-Mutation.html>
- <https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-receives-fda-fast-track-designation>
- <http://vp280.alertir.com/en/pressreleases/karolinska-development%27s-portfolio-company-aprea-therapeutics-receives-fda-breakthrough-therapy-designation-1769167>
- Parrales et al. Targeting Oncogenic Mutant p53 for Cancer Therapy. *Front Oncol.* 2015 Dec 21;5:288. doi: 10.3389/fonc.2015.00288. eCollection 2015. PMID: 26732534
- Zhao et al. Molecularly targeted therapies for p53-mutant cancers. *Cell. Mol. Life Sci.* 2017 Nov;74(22):4171-4187. PMID: 28643165
- Louis et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol.* 2021 Aug 2;23(8):1231-1251. PMID: 34185076
- NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 2.2025]
- Döhner et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood.* 2022 Sep 22;140(12):1345-1377. PMID: 35797463
- NCCN Guidelines® - NCCN-Myelodysplastic Syndromes [Version 2.2025]
- NCCN Guidelines® - NCCN-Myeloproliferative Neoplasms [Version 1.2025]
- NCCN Guidelines® - NCCN-Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Version 2.2025]
- NCCN Guidelines® - NCCN-Acute Lymphoblastic Leukemia [Version 3.2024]
- NCCN Guidelines® - NCCN-B-Cell Lymphomas [Version 2.2025]
- Bernard et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. *Nat. Med.* 2020 Aug 3. PMID: 32747829
- Paterni et al. Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential. *Steroids.* 2014 Nov;90:13-29. PMID: 24971815

References (continued)

31. Dahlman-Wright et al. International Union of Pharmacology. LXIV. Estrogen receptors. *Pharmacol. Rev.* 2006 Dec;58(4):773-81. PMID: 17132854
32. Marino et al. Estrogen signaling multiple pathways to impact gene transcription. *Curr. Genomics.* 2006;7(8):497-508. PMID: 18369406
33. Chang. Tamoxifen resistance in breast cancer. *Biomol Ther (Seoul).* 2012 May;20(3):256-67. PMID: 24130921
34. Toy et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. *Nat. Genet.* 2013 Dec;45(12):1439-45. PMID: 24185512
35. Jeselsohn et al. Emergence of Constitutively Active Estrogen Receptor- α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer. *Clin. Cancer Res.* 2014 Apr 1;20(7):1757-1767. PMID: 24398047
36. Robinson et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. *Nat Genet.* 2013 Dec;45(12):1446-51. doi: 10.1038/ng.2823. Epub 2013 Nov 3. PMID: 24185510
37. Hartmaier et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. *Ann. Oncol.* 2018 Apr 1;29(4):872-880. PMID: 29360925
38. Matissek et al. Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. *Cancer Discov.* 2018 Mar;8(3):336-353. PMID: 29242214
39. Lei et al. ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer. *Mol Cell Oncol.* 2018;5(6):e1526005. PMID: 30525098
40. Lei et al. Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. *Cell Rep.* 2018 Aug 7;24(6):1434-1444.e7. PMID: 30089255
41. Basudan et al. Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. *Mol. Cancer Res.* 2019 Feb;17(2):457-468. PMID: 30355675
42. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s001lbl.pdf
43. NCCN Guidelines® - NCCN-Breast Cancer [Version 3.2025]
44. <https://www.accutarbio.com/accutar-biotechnology-receives-fda-fast-track-designation-for-ac699-in-er-her2-breast-cancer/>
45. <https://sermonixpharma.com/sermonix-receives-fda-fast-track-designation-for-investigational-drug-lasofloxifene/>
46. <https://www.astrazeneca.com/content/dam/az/PDF/2022/h1-2022/H1-2022-results-announcement.pdf>
47. <https://www.businesswire.com/news/home/20160106006206/en/Innocrin-Pharmaceuticals-Granted-Fast-Track-Designation-FDA>
48. https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/17970s37s44s49lbl.pdf
49. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf
50. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020726s043lbl.pdf
51. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020753s025lbl.pdf
52. Tamoxifen—an update on current data and where it can now be used. *Breast Cancer Res. Treat.* 2002 Oct;75 Suppl 1:S7-12; discussion S33-5. PMID: 12353826
53. Kim et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. *J. Clin. Oncol.* 2011 Nov 1;29(31):4160-7. PMID: 21947828
54. Jeselsohn et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. *Nat Rev Clin Oncol.* 2015 Oct;12(10):573-83. PMID: 26122181
55. Angus et al. ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients. *Cancer Treat. Rev.* 2017 Jan;52:33-40. PMID: 27886589
56. Reinert et al. Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. *Front Oncol.* 2017 Mar 15;7:26. PMID: 28361033
57. Zhao et al. Zinc Finger Homeodomain Factor Zfhx3 Is Essential for Mammary Lactogenic Differentiation by Maintaining Prolactin Signaling Activity. *J Biol Chem.* 2016 Jun 10;291(24):12809-12820. PMID: 27129249
58. Miura et al. Cloning and characterization of an ATBF1 isoform that expresses in a neuronal differentiation-dependent manner. *J Biol Chem.* 1995 Nov 10;270(45):26840-8. PMID: 7592926
59. Berry et al. Positive and negative regulation of myogenic differentiation of C2C12 cells by isoforms of the multiple homeodomain zinc finger transcription factor ATBF1. *J Biol Chem.* 2001 Jul 6;276(27):25057-65. PMID: 11312261
60. Kataoka et al. Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1. *Oncogene.* 2001 Feb 15;20(7):869-73. PMID: 11314020

References (continued)

61. Ninomiya et al. Regulation of the alpha-fetoprotein gene by the isoforms of ATBF1 transcription factor in human hepatoma. *Hepatology*. 2002 Jan;35(1):82-7. PMID: 11786962
62. Kaspar et al. Myb-interacting protein, ATBF1, represses transcriptional activity of Myb oncoprotein. *J Biol Chem*. 1999 May 14;274(20):14422-8. PMID: 10318867
63. Sun et al. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. *Nat Genet*. 2005 Apr;37(4):407-12. PMID: 15750593
64. Mabuchi et al. Tumor suppressor, AT motif binding factor 1 (ATBF1), translocates to the nucleus with runt domain transcription factor 3 (RUNX3) in response to TGF-beta signal transduction. *Biochem Biophys Res Commun*. 2010 Jul 23;398(2):321-5. PMID: 20599712
65. Sun et al. Deletion of atbf1/zfhx3 in mouse prostate causes neoplastic lesions, likely by attenuation of membrane and secretory proteins and multiple signaling pathways. *Neoplasia*. 2014 May;16(5):377-89. PMID: 24934715
66. Kawaguchi et al. A diagnostic marker for superficial urothelial bladder carcinoma: lack of nuclear ATBF1 (ZFHX3) by immunohistochemistry suggests malignant progression. *BMC Cancer*. 2016 Oct 18;16(1):805. PMID: 27756245
67. Lander et al. Initial sequencing and analysis of the human genome. *Nature*. 2001 Feb 15;409(6822):860-921. PMID: 11237011
68. Baudrin et al. Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer. *Front Oncol*. 2018 Dec 12;8:621. doi: 10.3389/fonc.2018.00621. eCollection 2018. PMID: 30631754
69. Nojadeh et al. Microsatellite instability in colorectal cancer. *EXCLI J*. 2018;17:159-168. PMID: 29743854
70. Saeed et al. Microsatellites in Pursuit of Microbial Genome Evolution. *Front Microbiol*. 2016 Jan 5;6:1462. doi: 10.3389/fmicb.2015.01462. eCollection 2015. PMID: 26779133
71. Boland et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res*. 1998 Nov 15;58(22):5248-57. PMID: 9823339
72. Halford et al. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. *Cancer Res*. 2002 Jan 1;62(1):53-7. PMID: 11782358
73. Imai et al. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. *Carcinogenesis*. 2008 Apr;29(4):673-80. PMID: 17942460
74. NCCN Guidelines® - NCCN-Colon Cancer [Version 2.2025]
75. Pawlik et al. Colorectal carcinogenesis: MSI-H versus MSI-L. *Dis. Markers*. 2004;20(4-5):199-206. PMID: 15528785
76. Lee et al. Low-Level Microsatellite Instability as a Potential Prognostic Factor in Sporadic Colorectal Cancer. *Medicine (Baltimore)*. 2015 Dec;94(50):e2260. PMID: 26683947
77. Latham et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. *J. Clin. Oncol*. 2019 Feb 1;37(4):286-295. PMID: 30376427
78. Cortes-Ciriano et al. A molecular portrait of microsatellite instability across multiple cancers. *Nat Commun*. 2017 Jun 6;8:15180. doi: 10.1038/ncomms15180. PMID: 28585546
79. Bonneville et al. Landscape of Microsatellite Instability Across 39 Cancer Types. *JCO Precis Oncol*. 2017;2017. PMID: 29850653
80. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf
81. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125554s127lbl.pdf
82. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s009lbl.pdf
83. NCCN Guidelines® - NCCN-Rectal Cancer [Version 2.2025]
84. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s132lbl.pdf
85. Ribic et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *N. Engl. J. Med*. 2003 Jul 17;349(3):247-57. PMID: 12867608
86. Klingbiel et al. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. *Ann. Oncol*. 2015 Jan;26(1):126-32. PMID: 25361982
87. Hermel et al. The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer. *J Pers Med*. 2019 Jan 16;9(1). PMID: 30654522
88. Ciardiello et al. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. *Cancer Treat. Rev*. 2019 Jun;76:22-32. PMID: 31079031
89. King et al. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. *Science*. 1985 Sep 6;229(4717):974-6. PMID: 2992089

References (continued)

90. Gutierrez et al. HER2: biology, detection, and clinical implications. *Arch. Pathol. Lab. Med.* 2011 Jan;135(1):55-62. PMID: 21204711
91. Di et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. *Science*. 1987 Jul 10;237(4811):178-82. PMID: 2885917
92. Hudziak et al. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. *Proc. Natl. Acad. Sci. U.S.A.* 1987 Oct;84(20):7159-63. PMID: 2890160
93. Lonardo et al. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. *New Biol.* 1990 Nov;2(11):992-1003. PMID: 1983208
94. Ciriello et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. *Cell*. 2015 Oct 8;163(2):506-19. PMID: 26451490
95. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*. 2014 Sep 11;513(7517):202-9. doi: 10.1038/nature13480. Epub 2014 Jul 23. PMID: 25079317
96. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature*. 2014 Mar 20;507(7492):315-22. doi: 10.1038/nature12965. Epub 2014 Jan 29. PMID: 24476821
97. Donna et al. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*. 2012 Jul 18;487(7407):330-7. PMID: 22810696
98. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature*. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9. PMID: 25079552
99. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. *Nature*. 2011 Jun 29;474(7353):609-15. PMID: 21720365
100. Petrelli et al. Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature. *Breast Cancer Res. Treat.* 2017 Nov;166(2):339-349. PMID: 28762010
101. Bose et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. *Cancer Discov.* 2013 Feb;3(2):224-37. doi: 10.1158/2159-8290.CD-12-0349. Epub 2012 Dec 7. PMID: 23220880
102. Hudis. Trastuzumab—mechanism of action and use in clinical practice. *N. Engl. J. Med.* 2007 Jul 5;357(1):39-51. PMID: 17611206
103. Slamon et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*. 1987 Jan 9;235(4785):177-82. PMID: 3798106
104. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf
105. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf
106. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf
107. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf
108. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf
109. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf
110. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf
111. <https://www.globenewswire.com/news-release/2016/06/01/845166/0/en/Galena-Biopharma-Receives-Fast-Track-Designation-for-NeuVax-nelipepimut-S-PRESENT-Clinical-Trial.html>
112. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf
113. <https://www.prnewswire.com/news-releases/fda-grants-arx788-fast-track-designation-for-her2-positive-metastatic-breast-cancer-301199951.html>
114. <https://www.targetedonc.com/view/her2targeted-antibody-zw25-earns-fda-fast-track-designation-in-gea>
115. <https://investors.blackdiamondtherapeutics.com/news-releases/news-release-details/black-diamond-therapeutics-granted-fast-track-designation-fda>
116. <https://www.prnewswire.com/news-releases/remegen-announces-us-fda-has-granted-breakthrough-therapy-designation-for-disitamab-vedotin-rc48-in-urothelial-cancer-301138315.html>
117. <https://ir.ambrx.com/news/news-details/2023/ACE-Breast-02-Pivotal-Phase-3-Study-of-Ambrxs-ARX788-for-the-Treatment-of-HER2-Positive-Metastatic-Breast-Cancer-Achieves-Positive-Results/default.aspx>
118. <https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-us-food-and-drug-administration-grants-fast-track-designation-to-ct-0508-for-the-treatment-of-patients-with-solid-tumors-301381843.html>
119. <https://www.prnewswire.com/news-releases/carisma-therapeutics-granted-fda-fast-track-designation-for-ct-0525-for-the-treatment-of-her2overexpressing-solid-tumors-302180804.html>

References (continued)

120. <https://www.biospace.com/article/releases/bayer-receives-u-s-fda-breakthrough-therapy-designation-for-bay-2927088-for-non-small-cell-lung-cancer-harboring-her2-activating-mutations>
121. Ma et al. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. *Clin. Cancer Res.* 2017 Oct 1;23(19):5687-5695. PMID: 28679771
122. De et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. *Lung Cancer.* 2012 Apr;76(1):123-7. PMID: 22325357
123. Kris et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. *Ann. Oncol.* 2015 Jul;26(7):1421-7. PMID: 25899785
124. Falchook et al. Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. *J Thorac Oncol.* 2013 Feb;8(2):e19-20. PMID: 23328556
125. David et al. Neratinib in HER2- or HER3-mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 'basket' study. AACR 2017. Abstract CT001
126. Lin et al. Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report. *Onco Targets Ther.* 2019;12:10897-10902. PMID: 31849493
127. Chang et al. Sustained Partial Response to Afatinib in a Patient With Lung Adenocarcinoma Harboring HER2V659E Mutation. *JCO Precis Oncol.* 2020 Aug; 912-915. DOI: 10.1200/PO.20.00114
128. Nayar et al. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies. *Nat. Genet.* 2019 Feb;51(2):207-216. PMID: 30531871
129. <https://www.boehringer-ingelheim.com/us/human-health/cancer/why-cancer-care-personal-us>